Andrew I. Schafer

Andrew I. Schafer's AcademicInfluence.com Rankings

Andrew I. Schafer

Philosophy

#6893

World Rank

#10011

Historical Rank

Logic

#3986

World Rank

#5225

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Andrew I. Schafer's Degrees

Doctorate Medicine University of California, San Francisco
PhD Biochemistry University of California, San Francisco

Why Is Andrew I. Schafer Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Andrew I. Schafer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. (1987) (954)
Platelets and shear stress. (1996) (940)
Bleeding and thrombosis in the myeloproliferative disorders. (1984) (433)
Biochemical mechanisms of platelet activation. (1989) (387)
Effects of Nonsteroidal Antiinflammatory Drugs on Platelet Function and Systemic Hemostasis (1995) (338)
The hypercoagulable states. (1985) (331)
Nitric oxide induces heme oxygenase-1 gene expression and carbon monoxide production in vascular smooth muscle cells. (1997) (321)
Morning increase in platelet aggregability. Association with assumption of the upright posture. (1988) (317)
Clinical consequences of acquired transfusional iron overload in adults. (1981) (292)
von Willebrand factor binding to platelet GpIb initiates signals for platelet activation. (1991) (288)
Thrombosis and Hemorrhage (2002) (275)
Vascular smooth muscle cell heme oxygenases generate guanylyl cyclase-stimulatory carbon monoxide. (1995) (243)
Goldman-Cecil Medicine (2015) (223)
Leukotriene B4 stimulates polymorphonuclear leukocyte adhesion to cultured vascular endothelial cells. (1984) (218)
Hemodynamic forces induce the expression of heme oxygenase in cultured vascular smooth muscle cells. (1997) (215)
Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. (1987) (197)
Hyperhomocysteinemia accelerates atherosclerosis in cystathionine beta-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation. (2003) (183)
Inhibition of platelet function by organic nitrate vasodilators. (1980) (178)
Adenovirus-Mediated Heme Oxygenase-1 Gene Delivery Inhibits Injury-Induced Vascular Neointima Formation (2001) (178)
The prethrombotic state in cancer. (1990) (176)
Hyperhomocysteinemia Decreases Circulating High-Density Lipoprotein by Inhibiting Apolipoprotein A-I Protein Synthesis and Enhancing HDL Cholesterol Clearance (2006) (176)
Carbon monoxide inhibits apoptosis in vascular smooth muscle cells. (2002) (174)
Identification of platelet receptors for prostaglandin I2 and D2. (1979) (173)
Uremic bleeding: pathogenesis and therapy. (1998) (173)
Antiplatelet therapy. (1996) (165)
Heme oxygenase-1-derived carbon monoxide is an autocrine inhibitor of vascular smooth muscle cell growth. (2002) (162)
Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. (2006) (153)
Plasmin inhibition of platelet function and of arachidonic acid metabolism. (1985) (153)
Regulation of homocysteine metabolism and methylation in human and mouse tissues (2010) (153)
Hyperhomocystinemia Impairs Endothelial Function and eNOS Activity via PKC Activation (2005) (150)
Effects of nonsteroidal anti-inflammatory therapy on platelets. (1999) (148)
Effects of recombinant human granulocyte and macrophage colony-stimulating factors on signal transduction pathways in human granulocytes. (1987) (146)
Hemodialysis-associated platelet activation and thrombocytopenia. (1985) (146)
Heme oxygenase-1 attenuates vascular remodeling following balloon injury in rat carotid arteries. (2001) (142)
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene. (2007) (138)
Paraneoplastic thrombocytosis: the secrets of tumor self-promotion. (2014) (130)
Unidirectional transfer of prostaglandin endoperoxides between platelets and endothelial cells. (1984) (127)
Platelet protein phosphorylation, elevation of cytosolic calcium, and inositol phospholipid breakdown in platelet activation induced by plasmin. (1986) (126)
Hyperhomocysteinemia Promotes Inflammatory Monocyte Generation and Accelerates Atherosclerosis in Transgenic Cystathionine &bgr;-Synthase–Deficient Mice (2009) (125)
In vivo two-photon excited fluorescence microscopy reveals cardiac- and respiration-dependent pulsatile blood flow in cortical blood vessels in mice. (2012) (124)
The role of platelets in thrombotic and vascular disease. (1979) (122)
Transforming Growth Factor-β1 Stimulates l-Arginine Transport and Metabolism in Vascular Smooth Muscle Cells (2001) (122)
Physiological cyclic stretch causes cell cycle arrest in cultured vascular smooth muscle cells. (2000) (120)
Deficiency of platelet lipoxygenase activity in myeloproliferative disorders. (1982) (120)
Hemin Upregulates Egr-1 Expression in Vascular Smooth Muscle Cells via Reactive Oxygen Species ERK-1/2–Elk-1 and NF-&kgr;B (2008) (118)
Carbon monoxide and vascular cell function (review). (1998) (109)
Protein kinase C is activated in platelets subjected to pathological shear stress. (1993) (107)
Endoplasmic Reticulum Stress Stimulates Heme Oxygenase-1 Gene Expression in Vascular Smooth Muscle (2005) (97)
Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. (1995) (94)
Effects on platelet aggregation and fibrinolytic activity during upright posture and exercise in healthy men. (1992) (94)
Hypercoagulable states: molecular genetics to clinical practice (1994) (92)
The induction of nitric oxide synthase activity is inhibited by TGF-β1, PDGFAB and PDGFBB in vascular smooth muscle cells (1992) (92)
The vanishing physician-scientist? (2010) (90)
Physiological cyclic stretch directs L‐arginine transport and metabolism to collagen synthesis in vascular smooth muscle (2000) (89)
Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. (1995) (88)
Physiologic cyclic stretch inhibits apoptosis in vascular endothelium (2003) (86)
IL-1 and related cytokines enhance thrombin-stimulated PGI2 production in cultured endothelial cells without affecting thrombin-stimulated von Willebrand factor secretion or platelet-activating factor biosynthesis. (1989) (82)
cAMP induces heme oxygenase-1 gene expression and carbon monoxide production in vascular smooth muscle. (1997) (81)
Platelet-derived Growth Factor Regulates Vascular Smooth Muscle Cell Proliferation by Inducing Cationic Amino Acid Transporter Gene Expression (*) (1996) (80)
Therapy of chronic relapsing thrombotic thrombocytopenic purpura with prednisone and azathioprine (1985) (79)
Platelet‐derived growth factor stimulates LAT1 gene expression in vascular smooth muscle: Role in cell growth (2004) (78)
Arachidonic acid stimulates mucin secretion in prairie dog gallbladder. (1983) (77)
Hemostatic complications in young patients with essential thrombocythemia. (1990) (77)
Hyperhomocysteinemia impairs endothelium-derived hyperpolarizing factor-mediated vasorelaxation in transgenic cystathionine beta synthase-deficient mice. (2011) (76)
Endothelial cell adenylate cyclase: activation by catecholamines and prostaglandin I2+. (1980) (74)
Platelet-derived growth factor stimulates heme oxygenase-1 gene expression and carbon monoxide production in vascular smooth muscle cells. (1999) (73)
Thrombocytosis and thrombocythemia. (2001) (72)
Second messenger function of phosphatidic acid in platelet activation (1989) (72)
Platelet resistance to prostaglandin D2 in patients with myeloproliferative disorders (1978) (71)
Thrombotic disorders: diagnosis and treatment. (2003) (70)
PGE1 accelerates thrombolysis by tissue plasminogen activator. (1989) (67)
Differential regulation of L-arginine transport and nitric oxide production by vascular smooth muscle and endothelium. (1996) (65)
Transforming growth factor-beta(1) stimulates L-arginine transport and metabolism in vascular smooth muscle cells: role in polyamine and collagen synthesis. (2001) (65)
Cyclin A transcriptional suppression is the major mechanism mediating homocysteine-induced endothelial cell growth inhibition. (2002) (62)
A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with clinical trials. (1999) (61)
YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function. (2002) (61)
Vascular lipoxygenase activity: synthesis of 15-hydroxyeicosatetraenoic acid from arachidonic acid by blood vessels and cultured vascular endothelial cells. (1987) (59)
Endothelium-derived relaxing factor inhibits thrombin-induced platelet aggregation by inhibiting platelet phospholipase C. (1992) (58)
Teratogenic effects of antileukemic chemotherapy. (1981) (57)
Differential regulation of L-arginine transport and inducible NOS in cultured vascular smooth muscle cells. (1995) (56)
Antiapoptotic Action of Carbon Monoxide on Cultured Vascular Smooth Muscle Cells (2003) (54)
Lysophosphatidylcholine Regulates Cationic Amino Acid Transport and Metabolism in Vascular Smooth Muscle Cells (1997) (53)
The influence of chemotherapy on response of patients with hematologic malignancies to influenza vaccine (1979) (52)
Low-molecular-weight heparin--an opportunity for home treatment of venous thrombosis. (1996) (51)
YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation. (2000) (50)
Effect of alternate-day regular and enteric-coated aspirin on platelet aggregation, bleeding time, and thromboxane A2 levels in bleeding-time blood. (1986) (47)
Thrombin stimulates vascular smooth muscle cell polyamine synthesis by inducing cationic amino acid transporter and ornithine decarboxylase gene expression. (1998) (46)
Plasmin potentiates induction of nitric oxide synthesis by interleukin-1 beta in vascular smooth muscle cells. (1993) (46)
Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects. (1994) (42)
Prostacyclin and beta-adrenergic catecholamines inhibit arachidonate release and PGI2 synthesis by vascular endothelium (1981) (41)
Ethanol potentiates interleukin-1 beta-stimulated inducible nitric oxide synthase expression in cultured vascular smooth muscle cells. (1995) (40)
Heterogeneity of heparin lots associated with thrombocytopenia and thromboembolism. (1984) (39)
Differential Regulation of Homocysteine Transport in Vascular Endothelial and Smooth Muscle Cells (2007) (38)
Synergistic inhibition of platelet activation by plasmin and prostaglandin I2. (1987) (38)
Venous thrombosis as a chronic disease. (1999) (37)
Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two‐photon imaging (2014) (36)
Synthesis of a new series of potent inhibitors of thromboxane A2 biosynthesis (1983) (36)
Fibrinolysis inhibits shear stress-induced platelet aggregation. (1995) (34)
Genetic and acquired determinants of individual variability of response to antiplatelet drugs. (2003) (33)
Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload. (1985) (32)
Thrombocytosis and thrombocythemia. (1990) (32)
Cure of hemophilia A by orthotopic liver transplantation. (1988) (30)
Microvascular disturbances, thrombosis, and bleeding in thrombocythemia: current concepts and perspectives. (1997) (30)
Local administration of carbon monoxide inhibits neointima formation in balloon injured rat carotid arteries. (2005) (30)
Enhancement of thrombin‐ and lonomycin‐stimulated prostacyclin and platelet‐activating factor production in cultured endothelial cells by a tumor‐promoting phorbol ester (1990) (28)
Turnover of eicosanoid precursor fatty acids among phospholipid classes and subclasses of cultured human umbilical vein endothelial cells. (1989) (28)
Nonatheromatous arterial thrombosis. (1993) (27)
Incorporation of platelet and leukocyte lipoxygenase metabolites by cultured vascular cells (1986) (26)
Epinephrine and shear stress synergistically induce platelet aggregation via a mechanism that partially bypasses VWF-GP IB interactions. (1996) (26)
Antithrombotic therapy in patients with acute coronary syndromes. (2001) (26)
The Analysis of Ligand-Receptor Interactions in Platelet Activation (1995) (25)
Association of IgA Multiple Myeloma with Pre‐existing Disease (1979) (24)
Control of platelet protein kinase C activation by cyclic AMP. (1988) (24)
The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. (2021) (24)
Desensitization of prostaglandin-activated platelet adenylate cyclase. (1979) (24)
Platelet alpha 2 adrenoceptor characteristics during the morning increase in platelet aggregability. (1992) (24)
Platelet inhibition by an L-arginine-derived substance released by IL-1 beta-treated vascular smooth muscle cells. (1991) (23)
The effect of enteric-coated aspirin on the morning increase in platelet activity. (1991) (22)
Prostacyclin and beta-adrenergic catecholamines inhibit arachidonate release and PGI2 synthesis by vascular endothelium. (1981) (22)
Thrombin inhibits induction of nitric oxide synthase in vascular smooth muscle cells. (1993) (21)
Cyclic nucleotide regulation of interleukin-1 beta induced nitric oxide synthase expression in vascular smooth muscle cells. (1994) (21)
Inhibition of vascular endothelial cell prostacyclin synthesis by plasmin. (1989) (21)
Vascular endothelium: in defense of blood fluidity. (1997) (21)
Transforming growth factor-beta 1 stimulates vascular smooth muscle cell L-proline transport by inducing system A amino acid transporter 2 (SAT2) gene expression. (2001) (21)
Preferential incorporation of eicosanoid precursor fatty acids into human umbilical vein endothelial cell phospholipids. (1987) (20)
Platelets inhibit the induction of nitric oxide synthesis by interleukin-1β in vascular smooth muscle cells (1994) (20)
Severe hemolytic anemia following mitral valve repair. (1989) (20)
Selective induction of a cationic amino acid transporter by tumor necrosis factor-alpha in vascular endothelium. (1996) (18)
Monoclonal antibody AG-1 initiates platelet activation by a pathway dependent on glycoprotein IIb-IIIa and extracellular calcium. (1992) (17)
Comprar Goldman's Cecil Medicine, 24th Edition Expert Consult Premium Edition -- Enhanced Online Features and Print, Two Volume Set | Lee Goldman | 9781437727883 | Saunders (2011) (16)
Regulation of platelet arachidonic acid oxygenation by cyclic AMP. (1980) (16)
Platelet interaction with vascular smooth muscle in synthesis of prostacyclin. (1991) (16)
Platelet lipoxygenase-dependent oxygen burst. Evidence for differential activation of lipoxygenase in intact and disrupted human platelets. (1982) (15)
Regulation of the phosphoinositide cycle by Na+/H+ exchange and intracellular pH in human platelets. (1991) (15)
Platelet resistance to prostaglandin D2 in patients with myeloproliferative disorders. (1978) (15)
Warfarin for venous thromboembolism - walking the dosing tightrope. (2003) (14)
Monoclonal gammopathy in hereditary spherocytosis: a possible pathogenetic relation. (1978) (14)
Regulation of interleukin-1-beta-stimulated inducible nitric oxide synthase expression in cultured vascular smooth muscle cells by hemostatic proteins. (1996) (13)
Focussing of the clot: normal and pathologic mechanisms. (1987) (13)
Cyclic strain stimulates L-proline transport in vascular smooth muscle cells. (2004) (13)
Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents. (1997) (13)
The role of thrombin and thrombin inhibitors in coronary angioplasty. (1995) (12)
The induction of nitric oxide synthase activity is inhibited by TGF-beta 1, PDGFAB and PDGFBB in vascular smooth muscle cells. (1992) (11)
Translating basic discoveries into better health care: the APM's recommendations for improving translational research. (2004) (11)
The Cyclic GMP Modulators YC-1 and Zaprinast Reduce Vessel Remodeling Through Antiproliferative and Proapoptotic Effects (2009) (11)
Perspective: The Successful Physician-Scientist of the 21st Century (2010) (10)
Regulation of endothelial cell function by cyclic nucleotides (1984) (10)
Molecular mechanisms of hypercoagulable states (1997) (10)
Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm-Associated Pulmonary Hypertension. (2019) (9)
Thrombocytosis: When is an incidental finding serious? (2006) (9)
Incorporation of platelet and leukocyte lipoxygenase metabolites by cultured vascular cells. (1986) (9)
The Fault Lines of Academic Medicine (2002) (9)
Streptokinase inhibits acute platelet thrombus formation in stenosed dog coronary arteries. (1991) (8)
Crafting an effective strategic plan for a department of medicine. (2005) (8)
Thrombocytosis: too much of a good thing? (2002) (7)
current concepts Thrombocytosis (2004) (7)
Management of thrombocythemia (1996) (7)
Approach to Medicine, the Patient, and the Medical Profession (2012) (7)
Deployment of academic subspecialists in the emerging era of primary care. (1995) (7)
1 – Approach to Medicine, the Patient, and the Medical Profession: Medicine as a Learned and Humane Profession (2012) (7)
Endothelium-derived Relaxing Factor Inhibits Shear Stress-induced Platelet Aggregation. (1993) (6)
Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival (2019) (6)
174 – Approach to the Patient with Bleeding and Thrombosis (2012) (6)
Comprar Goldman's Cecil Medicine, 24th Edition Expert Consult Premium Edition -- Enhanced Online Features and Print, Single Volume | Andrew I. Schafer | 9781437716047 | Saunders (2011) (6)
Thrombotic, Vascular, and Bleeding Complications of the Myeloproliferative Neoplasms. (2021) (5)
Overview of Hemostasis and Fibrinolysis (2002) (5)
Platelets inhibit the induction of nitric oxide synthesis by interleukin-1 beta in vascular smooth muscle cells. (1994) (5)
Hairy cell leukemia: diagnosis and management. (1978) (5)
179 – Thrombotic Disorders: Hypercoagulable States (2012) (4)
Antiplatelet effects of fibrinolytic agents: a potential contributor to the hemostatic defect after thrombolysis. (1995) (4)
4. Translational Research and the Physician-Scientist (2016) (4)
Inhibition of plasminogen activator inhibitor-1 expression in vascular smooth muscle cells by protoporphyrins through a heme oxygenase-independent mechanism (2008) (4)
Comprar Goldman-Cecil Medicine, 2-Volume Set, 25th Edition | Andrew I. Schafer | 9781455750177 | Elsevier Internacional (2015) (4)
Acquired platelet storage pool deficiency due to severe valvular disease corrected by prosthetic valve replacement (1994) (4)
Low-molecular-weight heparin for venous thromboembolism. (1997) (4)
1. History of the Physician as Scientist (2016) (3)
The research community now and in the future: APM's recommendations for NIH priorities. (2003) (3)
Nitric oxide-independent regulation of the vascular injury response (2005) (3)
Transforming Growth Factor- b 1 Stimulates L -Arginine Transport and Metabolism in Vascular Smooth Muscle Cells Role in Polyamine and Collagen Synthesis (2001) (3)
Nitric oxide induces heme oxygenase-1 expression in vascular smooth muscle cells (1996) (2)
Current Education of Physicians: Lost in Translation? (2019) (2)
Synergistic Inhibition of Platelet Activation by Plasmin and Prostaglandin 12 1504 Blood (2005) (2)
Case 45-1985: A 56-Year-Old Man with Chronic Liver Disease and Diabetes Mellitus (1985) (2)
My doctor recently recommended that I take low-dose aspirin to minimize the risk of a heart attack or stroke. I routinely take ibuprofen for arthritis pain. Do I need both, and is it safe to combine the two? (2000) (2)
Incidence of Infections and Second Cancers in Philadelphia Chromosome-Negative Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib (2017) (1)
Book ReviewLeavell and Thorup's Fundamentals of Clinical Hematology (1987) (1)
Thrombosis and hemorrage (1998) (1)
Bleeding disorders. Finding the cause. (1984) (1)
178 – Hemorrhagic Disorders: Disseminated Intravascular Coagulation, Liver Failure, and Vitamin K Deficiency (2012) (1)
Blood Platelet Function and Medicinal Chemistry (1985) (1)
14. Revitalizing the Nation’s Physician-Scientist Workforce: The Association of Professors of Medicine Initiative (2016) (1)
Optimizing initial therapy of acute venous thromboembolism (2003) (1)
Physiological cyclic stretch inhibits vascular smooth muscle proliferation (1999) (0)
9. The Relationship between Physicians and PhD Scientists in Medical Research (2016) (0)
Recombinant Interferon-α Reduces Thrombotic Events in Patients with Polycythemia Vera (2019) (0)
Essential thrombocythemia. (1991) (0)
8. The Role of Academic Medical Centers and Medical Schools in the Training and Support of Physician-Scientists (2016) (0)
Regulation of Homocysteine Transport in Vascular Cells. (2006) (0)
In Vivo Imaging of Cerebral Circulation In Mouse Models of Polycythemia Vera (2010) (0)
Genetic Polymorphisms in Arterial Thrombosis and Vascular Disease (2001) (0)
Vascular Smooth Muscle Cells : Role in Polyamine and Collagen Synthesis Stimulates l-Arginine Transport and Metabolism in 1 β Transforming Growth Factor (2001) (0)
7. Engaging Undergraduate Students in Research: Sustaining Our Nation’s Pipeline of Future Biomedical Investigators (2016) (0)
arbon monoxide inhibits apoptosis in vascular smooth muscle cells (2002) (0)
IDIOPATHIC HYPEREOSINOPHILIC SYNDROME AS A CAUSE OF MYOCARDITIS (2015) (0)
C arbon monoxide inhibits apoptosis in vascular smooth muscle cells (2002) (0)
Jim Interview (2008) (0)
Transforming Growth Factor-&bgr;1 Stimulates l-Arginine Transport and Metabolism in Vascular Smooth Muscle Cells: Role in Polyamine and Collagen Synthesis (2001) (0)
Ruxolitinib Can Lead to Weight Gain in Patients with Myeloproliferative Neoplasms By Uncoupling Feeding from Central Leptin Signaling Via JAK2/STAT3 (2018) (0)
Transforming growth factor-β 1 stimulates vascular smooth muscle cell L-proline transport by inducing system A amino acid transporter 2 ( SAT 2 ) gene expression (0)
6. Generation X and the Millennials in Academic Medicine: Developing the Next Generation of Physician-Scientists (2016) (0)
15 A Half Century of Clinical Research (2016) (0)
13. Restoring and Invigorating an “Endangered Species”: Initiatives by the Association of American Medical Colleges (2016) (0)
11. Mentoring the Physician-Scientist: A Developmental Approach (2016) (0)
Symposium on Recent Advances in Disorders of Bleeding and Thrombosis: Introduction (1998) (0)
COMINGS AND GOINGS (1984) (0)
Genetic polymorphisms in arterial thrombosis and vascular disease. (2001) (0)
B κ Elk-1 and NF-− Oxygen Species ERK-1 / 2 Hemin Upregulates Egr-1 Expression in Vascular Smooth Muscle Cells via Reactive (2007) (0)
PRESIDENT'S ADDRESS FROM BUDAPEST TO VIENNA AND BACK. (2018) (0)
Homocysteine Inhibits Cyclin A Promoter Methylation Via DNMT3 Inactivation in Human Endothelial Cells. (2006) (0)
EPILOGUE. Looking Forward (2016) (0)
Abstract 16023: Hyperhomocysteinemia Aggravated Hyperglycemia-Induced Endothelial Dysfunction: Role of Calpain (2012) (0)
3. The Ecology of Physician-Scientists in Academic Medicine (2016) (0)
The academic job offer: what to expect and how to negotiate. (2009) (0)
Abstract 5813: Hyperhomocysteinemia Enhances Bone Marrow-derived and Vessel Resident Ly6C Inflammatory Monocyte Differentiation Contributing to Atherogenesis (2009) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Andrew I. Schafer?

Andrew I. Schafer is affiliated with the following schools: